VANCOUVER, British Columbia–(BUSINESS WIRE)–ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use in Chimeric Antigen Receptor (CAR) therapy. ME Therapeutics will continue developing the CD

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.